Completed PHASE3 INTERVENTIONAL 3-arm NCT00586664

Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis

Sponsor: Bausch & Lomb Incorporated

Interventions Bepotastine Besilate Ophthalmic Solution 1.0% Bepreve (bepotastine besilate ophthalmic solution) 1.5% placebo comparator

Updated 7 times since 2017 Last updated: Feb 4, 2013 Started: Oct 31, 2007 Primary completion: Jun 30, 2008 Completion: Jun 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00586664, this PHASE3 trial focuses on Allergic Conjunctivitis and remains completed. Sponsored by Bausch & Lomb Incorporated, it has been updated 7 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE3
Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bausch & Lomb Incorporated

Data source: Bausch & Lomb Incorporated

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Irvine, United States